Business
iSpecimen Inc. Announces Pricing of ~$5.5 Million Private Placement
WOBURN, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it entered into a securities purchase agreement with accredited investors for aggregate gross proceeds of approximately $5.5 million, before deducting fees to the placement agent and other offering expenses payable by the
About this update from Ispecimen Inc.
[{"type":"text","content":"WOBURN, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it entered into a securities purchase agreement with accredited investors for aggregate gross proceeds of approximately $5.5 million, before deducting fees to the placement agent and other offering expenses payable by the Company.","length":509,"tagName":"p"},{"type":"text","content":"In connection with the offering, the Company will issue 6,875 shares of newly designated Series C Convertible Preferred Stock (the “Preferred Stock”) at a price of $800 per share. Each share of Preferred Stock is convertible into shares of the Company’s common stock based on a $1,000 stated value per Preferred Stock share and a conversion price of 85% of the closing price of the common stock as of the date prior to each conversion date.","length":440,"tagName":"p"},{"type":"text","content":"The Company intends to use the net proceeds from the offering for marketing, working capital, and general corporate purposes.","length":125,"tagName":"p"},{"type":"text","content":"The offering is expected to close on or about December 31, 2025, subject to the satisfaction of customary closing conditions.","length":125,"tagName":"p"},{"type":"text","content":"E.F. Hutton & Co. is acting as the exclusive placement agent in connection with the offering.","length":97,"tagName":"p"},{"type":"text","content":"Additional details regarding the offering will be available in a Form 8-K to be filed by the Company with the Securities and Exchange Commission (the “SEC”).","length":157,"tagName":"p"},{"type":"text","content":"The securities to be issued in connection with the offering described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”), and Regulation D promulgated thereunder and have not been registered under the 1933 Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the 1933 Act and such applicable state securities laws. The s...